ClinicalTrials.gg
RecruitingNCT03526835Updated Nov 2, 2026

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of MCLA-158 and MCLA-158 + Pembrolizumab in Advanced/Metastatic Solid Tumors, Colorectal Cancer and Gastric Cancer, sponsored by Genmab. Recruiting at 54 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Genmab · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2018; still recruiting 8 years 6 months later.
Updated Nov 2, 2026Sponsor changedStudy contact changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
560
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing pembrolizumab in Colorectal Neoplasms — 5 open to participants now, 10 under way, 1 of them phase 3. pembrolizumab · Colorectal Neoplasms.

Planned enrollment
4th of 33
560 · median 45
Started
2018
with 2 others
Phase 1/2
4 of 33
1 open now
Registered
16th of 33
by date

Among the 33 studies testing pembrolizumab in Colorectal Neoplasms, this one is the 4th largest by planned enrollment, is one of 3 that started in 2018, is one of 4 in phase 1/2, and was the 16th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

5 of the 33 studies testing pembrolizumab in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing pembrolizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC.

The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer and metastatic colorectal cancer (mCRC).

The study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158 in monotherapy or in combination with other therapies.

Read the detailed description

Study Design:

This open label, multicenter, first-in-human study consists of 2 parts. Part 1 is a dose escalation to find the recommended Phase II dose (RP2D) of MCLA-158 studying patients with metastatic colorectal cancer (mCRC). Enrollment in the dose escalation part has been completed.

In the dose expansion (single-agent cohorts) part of the study, the activity, safety, and tolerability of MCLA-158 at 1500 mg every 2 weeks (Q2W) (preliminary RP2D) as a single agent will be evaluated in cohorts of selected solid tumor indications with dependency on EGFR signaling. The most recently enrolled cohorts were in patients with head and neck squamous cell carcinoma (HNSCC), gastric/ gastroesophageal junction adenocarcinoma (GEA) with EGFR amplification and/or high EGFR expression, esophageal carcinoma, and squamous cell carcinoma of the lung. In the dose expansion part of the study, safety was also characterized at two dose levels in (2L/3L) HNSCC. Enrollment is currently being explored in 2L/3L HNSCC and 3L/4L/5L mCRC (RAS/RAF wild type) patients. Additionally, in the dose expansion (combination cohorts) part of the study, the activity, safety, and tolerability of MCLA-158 at 1500 mg Q2W will be evaluated in combination with other therapies. Enrollment in the combination cohort of treatment of MCLA-158 with pembrolizumab for the treatment of patients with first line (1L) HNSCC is closed. Additionally, two combination cohorts of MCLA-158 with FOLFIRI or with FOLFOX chemotherapy (i.e., 5-fluorouracil [5-FU], leucovorin, and irinotecan (FOLFIRI) or oxaliplatin (FOLFOX)) will be explored in mCRC (RAS/RAF wild type) patients in the 1L/2L setting.

Other expansion cohorts may be considered for monotherapy or combination treatment in the future

03

Conditions studied

  • Advanced/Metastatic Solid Tumors
  • Colorectal Cancer
  • Gastric Cancer
  • Gastroesophageal-junction Cancer
  • NSCLC
  • HNSCC
  • Head and Neck Squamous Cell Carcinoma
  • Esophageal Cancer

Keywords

  • Bispecific antibody
  • First-in-human
  • MCLA-158
  • Antibodies
  • Bispecific
  • immunologic factors
  • Cytokines
  • EGFR
  • LGR5
04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed solid tumors with evidence of or locally advanced disease not amenable to standard therapy with curative intent.
  • A baseline fresh tumor sample (FFPE) from a metastatic or primary site (if safe/feasible).
  • Amenable for (if safe/feasible).
  • as defined by version 1.1 by radiologic methods.
  • (ECOG) performance status of 0 or 1.
  • ≥ 12 weeks, as per investigator.
  • (LVEF) ≥ 50% by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA).
  • Adequate organ function
  • Expansion cohorts: patients with locally advanced unresectable or metastatic disease for the following indications:

SINGLE AGENT:

  • SECOND-/ HNSCC PATIENTS (cohort closed to enrolment): patients who have progressed on or after, or are intolerant to, anti-PD-(L)1 therapy and platinum therapy as monotherapy or in combination with other agents and no previous exposure to EGFR inhibitors. Patients treated with platinum-containing therapy only in the setting, or in the context of multimodal therapy for locally advanced disease should have disease progression within 6 months of the last dose of platinum containing therapy. Patients with no more than 2 prior lines of treatment in recurrent or metastatic disease. • Human papilloma virus (HPV) status determined by p16 immunohistochemistry (IHC) or molecular HPV test for all oropharyngeal tumors should be reported when available.
  • The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.
  • 3L+ mCRC and 2L/3L HNSCC patients. (cohort open to enrolment) patients must have:
  • No oncogenic missense mutations in KRAS, NRAS, BRAF, or EGFR ectodomain, , as detected in plasma by ctDNA NGS central testing performed during screening.
  • A microsatellite stable (MSS) tumor.
  • Received ≥2 and no more than 4 lines of prior therapy in the metastatic setting including:

    1. Chemotherapy with oxaliplatin, irinotecan, and a fluoropyrimidine,
    2. Targeted therapy with an anti-VEGF therapy

COMBINATION:

  • FIRST-LINE HNSCC (cohort closed to enrolment): patients eligible to receive pembrolizumab as first-line monotherapy with tumors expressing programmed cell death protein ligand 1 (), combined positive score (CPS) ≥1, as determined by a Food and Drug Administration (FDA) approved test in the US, or by an approved equivalent test in other countries; patients should not have previous systemic therapy administered in the recurrent or metastatic setting, although previous systemic therapy as part of multimodal treatment for locally advanced disease is allowed if ended ≥6 months prior to signing the ICF. The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx. Previous treatments with anti PD-(L)1 or anti-EGFR therapies are not allowed.
  • mCRC (cohorts open to enrolment): Patients should have been previously diagnosed with histologically or cytologically confirmed unresectable or metastatic adenocarcinoma of the colon or rectum. Patients must be RAS/ RAF WT as determined using tumor tissue (primary or metastatic) by an appropriate tumor tissue based assay, to be confirmed by the sponsor, and must have an MSS tumor. Patients must be naive to prior anti-EGFR therapy.

    i. Cohort to be treated with petosemtamab and FOLFIRI: patients may have received up to 1 prior chemotherapy regimen for the metastatic setting, consisting of 1L fluoropyrimidine-oxaliplatin-based chemotherapy ± bevacizumab.

ii. Cohort to be treated with petosemtamab and FOLFOX: patients may have received up to 1 prior chemotherapy regimen in the metastatic setting consisting of 1L fluoropyrimidine-irinotecan-based chemotherapy ± bevacizumab

Exclusion criteria

Exclusion Criteria:

  • Central nervous system that are untreated or symptomatic, or require radiation, surgery, or continued therapy to control symptoms within 14 days of study entry.
  • Known .
  • Participation in another clinical study or treatment with any drug within 4 weeks prior to study entry.
  • Any systemic anticancer therapy within 4 weeks or 5 half-lives whichever is shorter of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity ( e.g. mitomycin C,nitrosoureas), or anticancer immunotherapies, a of 6 weeks is required.
  • Requirement for medication (e.g. methotrexate, cyclophosphamide)
  • Major surgery or radiotherapy within 3 weeks of the first dose of study treatment. Patients who received prior radiotherapy to ≥25% of bone marrow are not eligible, irrespective of when it was received.
  • Persistent grade >1 toxicities related to prior antineoplastic therapies (except for alopecia); stable sensory neuropathy ≤ grade 2 v4.03 is allowed.
  • History of reaction to any of the of petosemtamab, human proteins or any non-IMP treatment required for this study.
  • Uncontrolled hypertension (systolic blood pressure [BP] > 150 mmHg and/or diastolic BP > 100 mmHg) with appropriate treatment or unstable angina. History of congestive heart failure of Class II-IV (NYHA) criteria, or serious cardiac arrhythmia requiring treatment (except atrial fibrillation, paroxysmal supraventricular tachycardia). History of myocardial infarction within 6 months of study entry.
  • History of prior with the exception of excised cervical intraepithelial neoplasia or nonmelanoma skin cancer, or curatively treated cancer deemed at low risk for recurrence with no evidence of disease for 3 years.
  • Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy. Patients with a history of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or evidence of ILD on baseline chest computerized tomography (CT) scan.
  • Current serious illness or medical conditions including, but not limited to uncontrolled active infection,clinically significant pulmonary, metabolic or psychiatric disorders.
  • Patients with known infectious diseases:

    i. Active infection (hepatitis B surface antigen [HBsAg] positive) without receiving antiviral treatment. ii. Positive test for ribonucleic acid (HCV) RNA).

  • Pregnant or breastfeeding patients; patients of must use highly effective methods prior to study entry, for the duration of study participation, and for 6 months after the last dose of MCLA-158.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
560 participants (estimated)

Study arms

  • Experimental
    MCLA-158 (Single-Agent)

    In Part 1, the dose escalation phase, patients with metastatic CRC will receive escalating doses of MCLA-158 (every 2 weeks) until MTD or RP2D is reached. Each Cycle is 28 days. Single agent treatment. In Part 2, the expansion phase, participants with metastatic CRC and certain other solid tumors will receive intravenous infusion (i.v.) of MCLA-158 at the recommended Phase II dose (RP2D) every 2 weeks, at Day 1 and Day 15. The duration of each treatment cycle is 28 days. In addition, in the expansion phase, one randomized cohort will evaluate 2 doses (1100 mg and 1500 mg) of MCLA-158 in head and neck squamous cell carcinoma patients. Also in the expansion phase, a subcutaneous formulation of MCLA-158 will be evaluated.

    Drug: MCLA-158

  • Experimental
    MCLA-158 + Pembrolizumab

    MCLA-158 in combination with pembrolizumab will be explored first in head and neck squamous cell carcinoma patients eligible to receive pembrolizumab as first-line monotherapy.

    Combination Product: MCLA-158 + Pembrolizumab

  • Experimental
    MCLA-158 + FOLFIRI combination chemotherapy

    MCLA-158 in combination with FOLFIRI will be explored in mCRC patients with up to 1 line of prior regimen.

    Combination Product: MCLA-158 + FOLFIRI

  • Experimental
    MCLA-158 + FOLFOX combination chemotherapy

    MCLA-158 in combination with FOLFOX will be explored in mCRC patients with up to 1 line of prior regimen.

    Combination Product: MCLA-158 + FOLFOX

Interventions

  • full-length IgG1 bispecific antibody targeting EGFR and LGR5

    Also known as: petosemtamab

  • Combination productMCLA-158 + Pembrolizumab

    Drug pages: Petosemtamab · Pembrolizumab

    MCLA-158 in combination with pembrolizumab will be explored first in HNSCC patients eligible to receive pembrolizumab as first-line monotherapy.

    Also known as: petosemtamab

  • Combination productMCLA-158 + FOLFIRI

    Drug page: Petosemtamab

    MCLA-158 in combination with FOLFIRI will be explored in mCRC patients with up to 1 line of prior regimen.

    Also known as: petosemtamab

  • Combination productMCLA-158 + FOLFOX

    Drug pages: Petosemtamab · Folfox protocol

    MCLA-158 in combination with FOLFOX will be explored in mCRC patients with up to 1 line of prior regimen.

    Also known as: petosemtamab

06

What researchers measure

Primary outcomes

  1. Escalation: Number of patients with Dose Limiting Toxicities (DLTs) during Cycle 1

    Evaluation of the number and severity of participants with treatment related toxicities observed during the dose escalation.

    Time frame: 4 weeks

  2. Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer, and combination cohorts): Safety and tolerability: AEs and SAEs

    Incidence, severity, and relationship of AEs and SAEs

    Time frame: 6-12 months

  3. Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): Treatment discontinuations and dose modifications due to AEs

    Treatment discontinuations due to AEs and dose modifications due to AEs

    Time frame: 6-12 months

  4. Expansion (single agent - randomized expansion in 2/3L Head and Neck cancer): Best overall response (BOR)

    Evaluation of clinical benefit assessed by RECIST v1.1 determining Best overall response (BOR)

    Time frame: 36 months

  5. Expansion (Single agent - non-randomized, and combination cohorts): Objective response rate (ORR)

    Evaluation of clinical benefit assessed by RECIST v1.1 determining objective response rate (ORR)

    Time frame: 36 months

  6. Expansion (single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-safety relationship of petosemtamab administered at 1100 mg and 1500 mg: TEAEs

    Incidence of TEAEs at Week 8

    Time frame: 8 weeks

  7. Expansion: (subcutaneous cohort): Bioavailability of subcutaneous vs intravenous administration

    Bioavailability of subcutaneous vs intravenous administration

    Time frame: 6 weeks

  8. Expansion: (subcutaneous cohort): Area under the concentration versus time curve from time zero to time t [AUC0-t]

    Area under the concentration versus time curve from time zero to time t \[AUC0-t\]

    Time frame: 6 weeks

  9. Expansion: (subcutaneous cohort): Maximum plasma concentration [Cmax]

    Maximum plasma concentration as measured from all individual plasma concentrations

    Time frame: 8 weeks

  10. Expansion: (subcutaneous cohort): Minimum plasma drug concentration [Ctrough]

    Minimum plasma concentration as measured from all individual plasma concentrations

    Time frame: 6 weeks

Secondary outcomes

  1. Escalation & Expansion: (subcutaneous cohort): Best Overall Response (BOR)

    Evaluation of clinical benefit assessed by RECIST v1.1 determining Best overall response (BOR)

    Time frame: 36 months

  2. Expansion: Duration of response (DOR)

    Evaluation of clinical benefit assessed by RECIST v1.1 determining duration of response (DOR)

    Time frame: 36 months

  3. Expansion: Progression Free Survival (PFS)

    Evaluation of clinical benefit assessed by RECIST v1.1 determining progression free survival (PFS)

    Time frame: 36 months

  4. Expansion (mCRC combination cohorts): Progression Free Survival (PFS) rate at 4 months

    Evaluation of clinical benefit assessed by RECIST v1.1 determining progression free survival (PFS) rate at 4 months

    Time frame: 4 months

  5. Expansion (Single agent - non-randomized cohorts): Overall survival (OS)

    Evaluation of clinical benefit determining overall survival (OS)

    Time frame: 36 months

  6. Escalation & Expansion (single agent - non-randomized cohorts): Safety and tolerability: AEs and SAEs

    Incidence, severity, and relationship of AEs and SAEs

    Time frame: up to 30 days post-last dose

  7. Escalation & Expansion (Single agent - non-randomized and Combination cohorts): Treatment discontinuations and dose modifications due to AEs

    Treatment discontinuations due to AEs and dose modifications due to AEs

    Time frame: up to 30 days post-last dose

  8. Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-efficacy relationship of petosemtamab administered at 1100 mg and 1500 mg: Target Lesions

    Percentage change from baseline in sum of the diameters of target lesions at Week 8

    Time frame: 8 weeks

  9. Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-safety relationship of petosemtamab administered at 1100 mg and 1500 mg: Grade 3-4 TEAEs

    Incidence of Grade 3-4 TEAEs at Week 8

    Time frame: 8 weeks

  10. Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-safety relationship of petosemtamab administered at 1100 mg and 1500 mg: IRR TEAEs

    Incidence of IRR TEAEs at Week 8

    Time frame: 8 weeks

  11. Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-safety relationship of petosemtamab administered at 1100 mg and 1500 mg : non-IRR TEAEs

    Incidence of non-IRR TEAEs at Week 8

    Time frame: 8 weeks

  12. Escalation and Expansion: Safety and tolerability: laboratory values

    Number of participants with abnormal laboratory tests results

    Time frame: 6-12 months

  13. Escalation and Expansion: Safety and tolerability: (ECG)

    Number of participants with abnormal ECG readings

    Time frame: 6-12 months

  14. Escalation and Expansion: Safety and tolerability: vital signs

    Number of participants with abnormal vital signs

    Time frame: 6-12 months

  15. Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): Objective response rate (ORR)

    Evaluation of clinical benefit assessed by RECIST v1.1 determining objective response rate (ORR)

    Time frame: 36 months

  16. Escalation & Expansion: Incidence of anti-drug antibodies against MCLA-158

    Number of participants with anti-drug antibodies against MCLA-158

    Time frame: 36 months

  17. Escalation: Cytokine Panel Expression Profile

    Evaluation of the cytokine expression profile

    Time frame: 36 months

  18. Escalation & Expansion: End of infusion (EOI) plasma concentration [Ceoi]

    End of infusion (EOI) plasma concentration \[Ceoi\] as measured from all individual plasma concentrations

    Time frame: 36 months

  19. Escalation & Expansion: Maximum plasma concentration [Cmax]

    Maximum plasma concentration as measured from all individual plasma concentrations

    Time frame: 36 months

  20. Escalation & Expansion: Plasma concentration at 0 hours [C0h]

    Plasma concentration at 0 hours \[C0h\] as measured from all individual plasma concentrations

    Time frame: 36 months

  21. Escalation & Expansion: Area under the concentration versus time curve from time zero to time t [AUC0-t]

    Area under the concentration versus time curve from time zero to time t \[AUC0-t\]

    Time frame: 36 months

  22. Escalation & Expansion: Area under the concentration versus time curve [AUC0-∞]

    Area under the concentration versus time curve \[AUC0-∞\]

    Time frame: 36 months

  23. Escalation & Expansion: Clearance of plasma [CL]

    Clearance of plasma \[CL\]

    Time frame: 36 months

  24. Escalation & Expansion: Volume of distribution at steady state [Vss]

    Volume of distribution at steady state \[Vss\]

    Time frame: 36 months

  25. Escalation & Expansion: Half-life [t1/2]

    Half-life \[t1/2\]

    Time frame: 36 months

07

Study locations

45 of 54 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2018 (actual). Primary completion is estimated for May 2028, 120 months after the start.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's planned 120 months is above that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2018
First posted
May 16, 2018
StartActual
May 2, 2018
Primary completionEst.
May 2028
CompletionEst.
Nov 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (2 now completed, 1 now active, not recruiting)
Show 3 sites
  • Florida Cancer Specialists · Fort Myers, United StatesActive, not recruiting→Completed
  • SSM OKC Hightower Clinical · Oklahoma City, United StatesRecruiting→Completed
  • Hopital La Timone · Marseille, FranceRecruiting→Active, not recruiting
Oct 20, 2026
Eligibility
2 inclusion criteria edited; 1 exclusion criterion edited, 1 removed
What changed in the criteria
Inclusion criteria
  • Edited3L+ mCRC and 2L/3L HNSCC patients. (cohort open to enrolment) patients must have:
  • EditedNo oncogenic missense mutations in KRAS, NRAS, BRAF, or EGFR ectodomain, and no HER2 (ERBB2) or KRAS amplification, as detected in plasma by ctDNA NGS central testing performed during screening.
Exclusion criteria
  • EditedActive hepatitis B infection (hepatitis B surface antigen [HBsAg] positive) without receiving antiviral treatment. ii. Positive test for hepatitis C ribonucleic acid (HCV) RNA).
  • RemovedPositive test for hepatitis C ribonucleic acid (HCV) RNA).
Oct 20, 2026
Primary outcomes
4 edited
What changed in the outcomes
  • EditedExpansion: (mCRC subcutaneous cohort): Bioavailability of subcutaneous vs intravenous administrationTime frame: 6 weeks
  • EditedExpansion: (mCRC subcutaneous cohort): Area under the concentration versus time curve from time zero to time t [AUC0-t]Time frame: 6 weeks
  • EditedExpansion: (mCRC subcutaneous cohort): Maximum plasma concentration [Cmax]Time frame: 8 weeks
  • EditedExpansion: (mCRC subcutaneous cohort): Minimum plasma drug concentration [Ctrough]Time frame: 6 weeks
Oct 20, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedEscalation & Expansion: (mCRC subcutaneous cohort): Best Overall Response (BOR)Time frame: 36 months
Oct 20, 2026
Contact
Study contact changed: e•••@genmab.com · •••2500→c•••@genmab.com · •••2728; removed U•••@genmab.com · •••4499. See the current contact
Nov 2, 2026
Sponsor
Merus B.V.→Genmab
Nov 2, 2026
Show all 2 updates
  1. Nov 2, 2026
    Sponsor Merus B.V.→Genmab
    Contact Study contact changed: e•••@genmab.com · •••2500→c•••@genmab.com · •••2728; removed U•••@genmab.com · •••4499. See the current contact
    + 1 other change: identifiers
  2. Oct 20, 2026
    3 sites changed recruiting status (2 now completed, 1 now active, not recruiting)
    Show 3 sites
    • Florida Cancer Specialists · Fort Myers, United StatesActive, not recruiting→Completed
    • SSM OKC Hightower Clinical · Oklahoma City, United StatesRecruiting→Completed
    • Hopital La Timone · Marseille, FranceRecruiting→Active, not recruiting
    Eligibility 2 inclusion criteria edited; 1 exclusion criterion edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • Edited3L+ mCRC and 2L/3L HNSCC patients. (cohort open to enrolment) patients must have:
    • EditedNo oncogenic missense mutations in KRAS, NRAS, BRAF, or EGFR ectodomain, and no HER2 (ERBB2) or KRAS amplification, as detected in plasma by ctDNA NGS central testing performed during screening.
    Exclusion criteria
    • EditedActive hepatitis B infection (hepatitis B surface antigen [HBsAg] positive) without receiving antiviral treatment. ii. Positive test for hepatitis C ribonucleic acid (HCV) RNA).
    • RemovedPositive test for hepatitis C ribonucleic acid (HCV) RNA).
    Primary outcomes 4 edited
    What changed in the outcomes
    • EditedExpansion: (mCRC subcutaneous cohort): Bioavailability of subcutaneous vs intravenous administrationTime frame: 6 weeks
    • EditedExpansion: (mCRC subcutaneous cohort): Area under the concentration versus time curve from time zero to time t [AUC0-t]Time frame: 6 weeks
    • EditedExpansion: (mCRC subcutaneous cohort): Maximum plasma concentration [Cmax]Time frame: 8 weeks
    • EditedExpansion: (mCRC subcutaneous cohort): Minimum plasma drug concentration [Ctrough]Time frame: 6 weeks
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedEscalation & Expansion: (mCRC subcutaneous cohort): Best Overall Response (BOR)Time frame: 36 months
    + 3 other changes: identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03526835
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
May 16, 2018
Start date
May 2, 2018
Primary completion
May 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Genmab Trial Information
Contact
clinicaltrials@genmab.com
+4570202728
Study Official
study director · Genmab

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Petosemtamab · Pembrolizumab · Folfox protocol

Start the discussion